---
title: "Rani Therapeutics says oral RT-114 obesity drug candidate tops matched injection exposure in Phase 1a data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292763284.md"
description: "Rani Therapeutics reported positive Phase 1a data for RT-114, an oral obesity drug candidate. The oral formulation achieved systemic exposure over 150% higher than a matched subcutaneous injection in healthy volunteers. No serious adverse events were reported, with treatment-related effects being mild and consistent with the GLP-1 class. The company is expanding Phase 1a to refine pharmacokinetics ahead of a Phase 1b study in obese patients, expected to start in 2026 with data anticipated in 2027."
datetime: "2026-07-15T12:01:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292763284.md)
  - [en](https://longbridge.com/en/news/292763284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292763284.md)
---

# Rani Therapeutics says oral RT-114 obesity drug candidate tops matched injection exposure in Phase 1a data

-   Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral RaniPill capsule delivering PG-102 for obesity. \* Oral RT-114 produced systemic exposure above 150% versus a matched 12 mg subcutaneous PG-102 dose in healthy volunteers. \* No serious adverse events reported; no adverse events attributed to the capsule; treatment-related events were mild, consistent with GLP-1 class. \* Phase 1a expanded with 15 volunteers receiving two 12 mg oral doses to refine oral-to-subcutaneous pharmacokinetics ahead of Phase 1b. \* Phase 1b repeat-dose study in patients with obesity expected to start in 2026; data anticipated in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)

## Related News & Research

- [Rani Therapeutics to present at Canaccord Genuity Annual Growth Conference](https://longbridge.com/en/news/295403455.md)
- [Top Insider Makes Bold Move on Rani Therapeutics Stock](https://longbridge.com/en/news/293691544.md)
- [Aquestive reports positive human factors, PK results for Anaphylm epinephrine sublingual film in healthy volunteers](https://longbridge.com/en/news/295396858.md)
- [Clinuvel flags superior release profile in VLRX-L injectable peptide platform study](https://longbridge.com/en/news/295603068.md)
- [Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio](https://longbridge.com/en/news/295023087.md)